Anabolic Steroids
Mestanolone
Mestanolone is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Epithio-17α-methyl-androstanol
Epithio-17α-methyl-androstanol is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Mesterolone
An orally active DHT-derived androgen used medically in some countries but not broadly approved in the United States. It is androgenic and can suppress endogenous gonadal signaling.
Trendione
Trendione is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Methandienone
An orally active 17α-alkylated anabolic steroid widely known from historical performance-enhancement use. It is not an FDA-approved dietary supplement and carries the class risks of anabolic-androgenic steroids.
13β-Ethyl-17β-hydroxygon-4-en-3-one
13β-Ethyl-17β-hydroxygon-4-en-3-one is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Methandriol
Methandriol is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Ethylestrenol
Ethylestrenol is listed in current U.S. federal Schedule III regulations as an anabolic steroid or covered anabolic-steroid substance. Compound-specific human evidence may be limited or historical.
Methasterone
A designer 17α-alkylated anabolic steroid also known as methyldrostanolone or Superdrol. Case literature and class pharmacology raise particular concern for liver and lipid effects.
Fluoxymesterone
A potent 17α-alkylated androgen with historical therapeutic use. Its pharmacology is androgen-receptor mediated; nonmedical exposure can carry substantial hepatic, lipid, cardiovascular and endocrine risk.